Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Br J Pharmacol ; 168(4): 932-45, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23004677

RESUMO

BACKGROUND AND PURPOSE: Neointima is considered a critical event in the development of vascular occlusive disease. Nectandrin B from nutmeg functions as a potent AMP-activated protein kinase (AMPK) activators. The present study addressed whether nectandrin B inhibits intimal hyperplasia in guide wire-injured arteries and examined its molecular mechanism. EXPERIMENTAL APPROACH: Neointima was induced by guide wire injury in mouse femoral arteries. Cell proliferation and mechanism studies were performed in rat vascular smooth muscle cells (VSMC) culture model. KEY RESULTS: Nectandrin B increased AMPK activity in VSMC. Nectandrin B inhibited the cell proliferation induced by PDGF and DNA synthesis. Moreover, treatment of nectandrin B suppressed neointima formation in femoral artery after guide wire injury. We have recently shown that Pin1 plays a critical role in VSMC proliferation and neointima formation. Nectandrin B potently blocked PDGF-induced Pin1 and cyclin D1 expression and nectandrin B's anti-proliferation effect was diminished in Pin1 overexpressed VSMC. PDGF-induced phosphorylation of ERK and Akt was marginally affected by nectandrin B. However, nectandrin B increased the levels of p53 and its downstream target p21 and, also reversibly decreased the expression of E2F1 and phosphorylated Rb in PDGF-treated VSMC. AMPK inhibition by dominant mutant form of adenovirus rescued nectandrin B-mediated down-regulation of Pin1 and E2F1. CONCLUSIONS AND IMPLICATIONS: Nectandrin B inhibited VSMC proliferation and neointima formation via inhibition of E2F1-dependent Pin1 gene transcription, which is mediated through the activation of an AMPK/p53-triggered pathway.


Assuntos
Artéria Femoral/efeitos dos fármacos , Lignanas/uso terapêutico , Músculo Liso Vascular/efeitos dos fármacos , Neointima/prevenção & controle , Peptidilprolil Isomerase/antagonistas & inibidores , Substâncias Protetoras/uso terapêutico , Proteínas Quinases/metabolismo , Quinases Proteína-Quinases Ativadas por AMP , Animais , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Ativação Enzimática , Artéria Femoral/lesões , Artéria Femoral/metabolismo , Artéria Femoral/patologia , Lignanas/administração & dosagem , Lignanas/farmacologia , Camundongos , Músculo Liso Vascular/enzimologia , Músculo Liso Vascular/metabolismo , Músculo Liso Vascular/patologia , Peptidilprolil Isomerase de Interação com NIMA , Neointima/enzimologia , Neointima/metabolismo , Neointima/patologia , Peptidilprolil Isomerase/biossíntese , Substâncias Protetoras/administração & dosagem , Substâncias Protetoras/farmacologia , Ratos , Lesões do Sistema Vascular/tratamento farmacológico , Lesões do Sistema Vascular/enzimologia , Lesões do Sistema Vascular/metabolismo , Lesões do Sistema Vascular/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA